- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05673057
MP0533-tutkimus potilailla, joilla on uusiutunut tai refraktaarinen akuutti myelooinen leukemia tai myelodysplastinen oireyhtymä
Vaiheen 1/2a, ensimmäinen ihmisessä, avoin, monikeskus, annoksen eskalaatiotutkimus MP0533:sta potilailla, joilla on uusiutunut/refraktorinen (R/R) akuutti myelooinen leukemia (AML) tai myelodysplastinen oireyhtymä (MDS)
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
- Lääke: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1
- Lääke: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A
- Lääke: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax
- Lääke: MP0533 with Obinutuzumab pretreatment
- Lääke: MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients
- Lääke: MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Amsterdam, Alankomaat
- Amsterdam UMC - Locatie VUmc
-
Rotterdam, Alankomaat
- Erasmus MC
-
-
Provincie Groningen
-
Groningen, Provincie Groningen, Alankomaat
- Groningen UMC
-
-
-
-
-
Vilnius, Liettua
- Vilnius University Hospital Santaros Klinikos
-
-
-
-
-
Bordeaux, Ranska
- CHU Bordeaux
-
Paris, Ranska, 75010
- AP-HP Hôpital Saint-Louis
-
Toulouse, Ranska
- IUCT Oncopole
-
-
-
-
Canton of Bern
-
Bern, Canton of Bern, Sveitsi, 3010
- Inselspital, Universitaetsspital Bern
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Sveitsi, 8006
- Universitaetsspital Zuerich
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Has signed and dated written informed consent prior to performing any study procedure, including screening
- Diagnosis of relapsed/refractory AML or relapsed/refractory MDS/AML according to the ELN recommendation 2022.
- Age ≥18 years old on the day of signing informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2
- Anticipated life expectancy ≥ 12 weeks by investigator judgement
- White blood count (WBC) ≤ 15G/L at day of trial drug infusion
- Adequate renal and hepatic function
- Is using highly effective contraception, for females of childbearing potential and for men
Exclusion Criteria:
- Mixed phenotype acute leukemia
- Patients with favorable AML mutations according to ELN recommendation 2022 and 2024
- Allogeneic HCT within the last 3 months and/or eligibility for standard 2nd line of targeted therapy, like gilteritinib for FLT3 mutated AML, unless this therapeutic option has already been given and proven ineffective (patient relapsed or resistant to), or contraindicated, or confounding mutations exist, or there is a lack of access to this recommended therapy.
- More than 2 prior lines of anti-leukemic therapy
- Active GvHD requiring immune-suppressive therapy
- Use of immunosuppressive drugs
- Clinical signs of AML in the central nervous system
- Major surgery within 28 days prior to start of study medication
- Other malignancy requiring active therapy, but adjuvant endocrine therapy is allowed
- Any uncontrolled active infection
- Treatment with investigational agents or agents targeting CD33, CD123 or CD70 within 4 weeks or five times the half-life of the agent, whichever is longer, prior to start of trial medication
- Left ventricular ejection fraction of < 50% on echocardiographic exam at screening
- History or evidence of clinically significant cardiovascular disease
- Pulmonary disease with clinically relevant hypoxia
- Active hepatitis
- Concurrent enrolment in another clinical trial, unless it is an observational (non-interventional) study or it is the follow-up period of an interventional study
- Known hypersensitivity to any of the excipients of the investigational medicinal product (IMP), i.e. finished MP0533 drug
Dose Expansion Group (Arm B in treatment-naïve patients only):
Inclusion
• Treatment-naïve patients who are eligible to AZA+VEN as standard of care
Dose Escalation and Expansion Groups (Arm B only):
Exclusion
- received VEN in prior treatment lines
- received strong and/or moderate CYP3A inducers within 7 days before the initiation of AZA/VEN regimen;
- Has consumed grapefruit, grapefruit products, Seville oranges or Starfruit within 3 days before the initiation of AZA/VEN regimen;
- Has a malabsorption syndrome or other condition that precludes the enteral route of administration of VEN.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Dose escalation (Part 1)
• MP0533 is administered by intravenous infusion |
MP0533 is administered by intravenous infusion
Muut nimet:
|
|
Kokeellinen: Dose escalation (Part 2 - Arm A)
|
Muut nimet:
|
|
Kokeellinen: Dose escalation (Part 2 - Arm B)
|
Muut nimet:
|
|
Kokeellinen: Dose expansion (Arm A)
|
Muut nimet:
|
|
Kokeellinen: Dose expansion (Arm B relapsed/refractory AML)
|
Muut nimet:
|
|
Kokeellinen: Dose expansion (Arm B in treatment naïve patients)
|
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Phase 1 dose escalation: Recommended Phase 2 Dose Regimen and/or Maximum Tolerated Dose Regimen
Aikaikkuna: from start of treatment to end of first cycle (day 1 - 28)
|
Incidence of dose limiting toxicities, assessment of toxicity/safety, pharmacokinetic and efficacy parameters |
from start of treatment to end of first cycle (day 1 - 28)
|
|
Phase 2 dose extension: Overall Response Rate
Aikaikkuna: throughout the study (on average 3 months)
|
Best overall response of complete remission (CR), complete remission with partial hematological recovery (CRh), complete remission with incomplete hematological recovery (CRi), morphologic leukemia-free state (MLFS) and partial remission (PR) according to the European LeukemiaNet (ELN) response criteria 2022 |
throughout the study (on average 3 months)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Serum Concentration-time profiles (max. serum)
Aikaikkuna: throughout the study (on average 1 year)
|
Determination of PK parameters including (but not limited to) maximum serum concentration (Cmax) |
throughout the study (on average 1 year)
|
|
Serum Concentration-time profiles (at Cmax (Tmax))
Aikaikkuna: throughout the study (on average 1 year)
|
Determination of PK parameters including (but not limited to) time at Cmax (Tmax) |
throughout the study (on average 1 year)
|
|
Serum Concentration-time profiles (min. serum concentration)
Aikaikkuna: throughout the study (on average 1 year)
|
Determination of PK parameters including (but not limited to) minimal serum concentration (Cmin) |
throughout the study (on average 1 year)
|
|
Area under the concentration-time curve (AUC)
Aikaikkuna: throughout the study (on average 1 year)
|
Pharmacokinetic (PK) analysis of MP0533 |
throughout the study (on average 1 year)
|
|
Total Clearance (CL)
Aikaikkuna: throughout the study (on average 1 year)
|
PK analysis of MP0533 |
throughout the study (on average 1 year)
|
|
Volume of distribution (Vd)
Aikaikkuna: throughout the study (on average 1 year)
|
PK analysis of MP0533 |
throughout the study (on average 1 year)
|
|
Half-life (t1/2)
Aikaikkuna: throughout the study (on average 1 year)
|
PK analysis of MP0533 |
throughout the study (on average 1 year)
|
|
Incidence of adverse events (AEs) as a measure of safety
Aikaikkuna: throughout the study (on average 1 year)
|
Type, incidence and severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 |
throughout the study (on average 1 year)
|
|
Event free survival (EFS)
Aikaikkuna: throughout the study (on average 1 year)
|
time from the date of first study treatment administration to the date of treatment failure, hematologic relapse from CR/CRh/CRi or death from any cause |
throughout the study (on average 1 year)
|
|
Duration of response (DoR)
Aikaikkuna: throughout the study (on average 1 year)
|
time from the start date of CR, CRh, CRi, MLFS or PR to relapse or death |
throughout the study (on average 1 year)
|
|
Overall survival (OS)
Aikaikkuna: throughout the study (up to 3 years)
|
time from the date of first study treatment administration to the date of death |
throughout the study (up to 3 years)
|
|
Transfusion-Independence (TI)
Aikaikkuna: throughout the study (on average 1 year)
|
portion of subjects who achieved RBC/platelet transfusion independence post baseline |
throughout the study (on average 1 year)
|
|
Number of patients proceeding to a stem cell transplantation
Aikaikkuna: throughout the study (on average 1 year)
|
Number of patients proceeding to a stem cell transplantation |
throughout the study (on average 1 year)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat
- Neoplasmat histologisen tyypin mukaan
- Hematologiset sairaudet
- Hemic- ja imusuutteet
- Leukemia
- Orgaaniset kemikaalit
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Nukleiinihapot, nukleotidit ja nukleosidit
- Syytidiini
- Pyrimidiininnukleosidit
- Pyrimidiinit
- AZA -yhdisteet
- Nukleosidit
- Ribonukleosidit
- Atsasitidiini
- Venetoclax
Muut tutkimustunnusnumerot
- MP0533-CP101
- 2022-002432-31 (EudraCT-numero)
- 2023-505259-39-00 (Ctis)
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .